Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRBU 
Caribou Biosciences Inc (CRBU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: CRBU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.86
1 Year Target Price $8.86
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.13% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 216.05M USD | Price to earnings Ratio - | 1Y Target Price 8.86 |
Price to earnings Ratio - | 1Y Target Price 8.86 | ||
Volume (30-day avg) 9 | Beta 2.59 | 52 Weeks Range 0.66 - 3.00 | Updated Date 10/31/2025 |
52 Weeks Range 0.66 - 3.00 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1328.38% |
Management Effectiveness
Return on Assets (TTM) -31.78% | Return on Equity (TTM) -68.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49567822 | Price to Sales(TTM) 23.69 |
Enterprise Value 49567822 | Price to Sales(TTM) 23.69 | ||
Enterprise Value to Revenue 5.43 | Enterprise Value to EBITDA -36.94 | Shares Outstanding 93123239 | Shares Floating 84057692 |
Shares Outstanding 93123239 | Shares Floating 84057692 | ||
Percent Insiders 9.81 | Percent Institutions 41.9 |
Upturn AI SWOT
Caribou Biosciences Inc
Company Overview
History and Background
Caribou Biosciences Inc. was founded in 2011 based on CRISPR technology licensed from UC Berkeley. They focus on developing off-the-shelf cell therapies for cancer and other diseases. They went public in 2021.
Core Business Areas
- Cell Therapy Development: Developing allogeneic CAR-T cell therapies targeting various cancers.
- CRISPR Platform: Advancing their CRISPR-Cas9 platform for genome editing.
Leadership and Structure
Rachel Haurwitz (President and CEO); The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- CB-010: An allogeneic anti-CD19 CAR-T cell therapy in Phase 1 clinical trials for relapsed or refractory B cell lymphoma. Market share is currently 0 due to being in development stage. Competitors include Kite Pharma (GILD), Novartis (NVS), and Bristol Myers Squibb (BMY) who have approved autologous therapies.
- CB-011: An allogeneic anti-BCMA CAR-T cell therapy in Phase 1 clinical trials for relapsed or refractory multiple myeloma. Market share is currently 0 due to being in development stage. Competitors include Johnson & Johnson (JNJ) and Bristol Myers Squibb (BMY) who have approved BCMA-targeting therapies.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in gene editing and immunotherapy. There is high demand for off-the-shelf allogeneic therapies.
Positioning
Caribou is positioned as a leader in allogeneic CAR-T cell therapy development, leveraging their CRISPR platform to create more precise and safer cell therapies. Their key advantage is their CRISPR-Cas9 technology, potentially leading to better editing efficiency and reduced off-target effects compared to competitors using TALEN or other CRISPR variants.
Total Addressable Market (TAM)
The total addressable market for cell therapies is expected to reach hundreds of billions of dollars. Caribou is positioned to capture a significant portion of this market with successful clinical trials and product launches.
Upturn SWOT Analysis
Strengths
- Proprietary CRISPR-Cas9 platform
- Strong intellectual property portfolio
- Experienced leadership team
- Promising early clinical trial data
Weaknesses
- Limited clinical data compared to competitors
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Manufacturing complexity
Opportunities
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Advancements in CRISPR technology
- Regulatory approvals for allogeneic therapies
Threats
- Competition from established cell therapy companies
- Clinical trial failures
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
- CRSP
- EDIT
Competitive Landscape
Caribou is competing in a rapidly evolving cell therapy market. Its proprietary CRISPR platform offers a potential advantage, but it faces significant competition from larger, more established companies.
Growth Trajectory and Initiatives
Historical Growth: Caribou's historical growth has been characterized by its advancements in its CRISPR platform and entry into clinical trials.
Future Projections: Future growth is dependent on positive clinical trial data, regulatory approvals, and potential partnerships. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include advancing its clinical pipeline, expanding its manufacturing capabilities, and strengthening its intellectual property portfolio.
Summary
Caribou Biosciences is a clinical-stage company pioneering allogeneic CAR-T cell therapies using its CRISPR-Cas9 platform. Its strengths lie in its innovative technology and promising early clinical data. However, it faces significant risks including clinical trial failures and competition. Successful development and commercialization of its therapies are critical for its long-term viability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Caribou Biosciences Inc
Exchange NASDAQ | Headquaters Berkeley, CA, United States | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO, President & Director Dr. Rachel E. Haurwitz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 147 | Website https://cariboubio.com |
Full time employees 147 | Website https://cariboubio.com | ||
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.